Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | CCR9 | P51686 | 2/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482801 | 0.91 | TBXA2R (0.44) | KDM4ETBXA2RDRD2PTGESCNR1 | |
| SCHEMBL1482913 | 0.91 | KDM4E (0.48) | KDM4ETBXA2RDRD2CCR9NR1H4 | |
| SCHEMBL1483050 | 0.89 | KDM4E (0.43) | KDM4ETBXA2RDRD2CCR9NR1H4 | |
| SCHEMBL1483423 | 0.88 | NR1H4 (0.42) | KDM4ECCR9CNR1NR1H4P2RX3 | |
| SCHEMBL1482836 | 0.88 | CCR2 (0.41) | KDM4ETBXA2RDRD2PTGESCNR1 | |
| SCHEMBL1482646 | 0.87 | DRD2 (0.53) | TBXA2RDRD2NR1H4P2RX3KMT2A | |
| SCHEMBL1483153 | 0.87 | KDM4E (0.45) | KDM4ETBXA2RDRD2CCR9HDAC1 | |
| SCHEMBL1482332 | 0.84 | DYRK1A (0.39) | KDM4ECNR1NR1H4P2RX3 | |
| SCHEMBL1482685 | 0.83 | KMT2A (0.48) | KDM4EPTGESKMT2A | |
| SCHEMBL1483030 | 0.82 | DRD2 (0.47) | TBXA2RDRD2CCR2P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | KDM4E 1791/4885TBXA2R 92/4885DRD2 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.